

2019

New Filovirus Disease Classification and Nomenclature

Jens H. Kuhn

Takuya Adachi

Neill K.J. Adhikari

Jose R. Arribas

Ibrahima Elhadj Bah

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles

 Part of the **Epidemiology Commons**

Authors

Jens H. Kuhn, Takuya Adachi, Neill K.J. Adhikari, Jose R. Arribas, Ibrahima Elhadj Bah, Daniel G. Bausch, Nahid Bhadelia, Matthias Borchert, Arne Broch Brantsæter, David Brett-Major, Timothy H. Burgess, Daniel S. Chertow, Christopher G. Chute, Theodore J. Cieslak, Robert Colebunders, Ian Crozier, Richard T. Davey, Hilde de Clerck, Rafael Delgado, Laura Evans, Mosoka Fallah, William A. Fischer, Tom E. Fletcher, Robert A. Fowler, Thomas Grünewald, Andy Hall, Angela L. Hewlett, Andy I.M. Hoepelman, Catherine F. Houlihan, Giuseppe Ippolito, Shevin T. Jacob, Michael Jacobs, Robert Jakob, Frederique A. Jacquerioz, Laurent Kaiser, Andre C. Kalil, Rashidatu F. Kamara, Jimmy Kapetshi, Hans-Dieter Klenk, Gary Kobinger, Mark G. Kortepeter, Colleen S. Kraft, Thomas Kratz, Henry S. Kyobe Bosa, Marta Lado, François Lamontagne, H. Cliff Lane, Leslie Lobel, Julius Lutwama, G. Marshall Lyon, Moses B.F. Massaquoi, Thomas A. Massaquoi, Aneesh K. Mehta, Vital Mondonge Makuma, Srinivas Murthy, Tonny Seikikongo Musoke, Jean-Jacques Muyembe-Tamfum, Phiona Nakyeyune, Carolina Nanclares, Miriam Nanyunja, Justus Nsio-Mbeta, Tim O'Dempsey, Janusz T. Pawęska, Clarence J. Peters, Peter Piot, Christophe Rapp, Bertrand Renaud, Bruce Ribner, Pardis C. Sabeti, John S. Schieffelin, Werner Slenczka, Moses J. Soka, Armand Sprecher, James Strong, Robert Swanepoel, Timothy M. Uyeki, Michel van Herp, Pauline Vetter, David A. Wohl, Timo Wolf, Anja Wolz, Alie H. Wurie, and Zabulon Yoti

New filovirus disease classification and nomenclature

Jens H. Kuhn ¹* et al.

The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision.

Former filovirus disease names

Filoviruses, the members of the family *Filoviridae*, are currently classified into one proposed and five established genera (Supplementary Table 1). Of the twelve described filoviruses, six have been identified as aetiological agents of naturally occurring human disease outbreaks.

The International Classification of Diseases (ICD; Supplementary Box 1) is primarily a statistical tabulation. Consequently, frequently observed diseases with large patient cohorts are more likely to have their own disease names, codes and subcategories of disease manifestations than uncommonly occurring diseases because larger cohorts ensure statistical reliability of disease descriptions. Given the past low number of filovirus disease outbreaks and overall case numbers (34 disease outbreaks until 2013, involving 2,872 cases and 1,968 deaths), it is not surprising that the diseases caused by filoviruses were not captured by early ICD iterations. In ICD-9, the only code defining filovirus diseases was '078.89 Other specified diseases due to viruses'. Consequently, various unofficial filovirus disease names have been used in the scientific literature (Supplementary Tables 2,3).

The currently used ICD-10 recognizes filovirus diseases specifically via entries 'A98.4 Ebola virus disease (EVD)' and 'A98.3 Marburg virus disease (MVD)' since 1994. However, ICD-10 does not specify which filoviruses are considered to cause which of the two diseases, offer disease definitions or account for unusual disease manifestations (for example, subclinical or persistent infections).

A need for new filovirus disease names

In 2014, Ebola virus (EBOV) was identified as the aetiological agent of an EVD outbreak in Western Africa that, from 2013 to 2016, caused at least 28,652 human infections and 11,325 deaths. This single outbreak involved almost ten times the combined number of patients from all previous filovirus disease outbreaks. Consequently, the clinical presentation of EVD could be refined using

statistical measures, and subclinical EBOV infections leading to sexual transmission or disease relapse were substantiated through clinical observations. In addition, often-debilitating sequelae in EVD survivors were observed longitudinally for the first time using large cohorts. As clinical research data on EVD accumulated, the coverage of filovirus disease in ICD-10 was inadequate to cover complex clinical presentations of filovirus disease.

Discussion framework

Expert panel and method. Responding to the WHO's public call for input in the development of ICD-11, we assembled a large group of experts (the authors) who treated filovirus-infected patients or were heavily involved in organizing the treatment of patients to develop ICD-11's entries on filovirus disease. Consensus was obtained by step-wise, simple-majority, semi-blind voting. The participants represented a wide spectrum of scientists and health workers of both sexes and from numerous countries, including African nations most affected by human filovirus infections.

Main issues. ICD-10 recognizes two filovirus diseases: EVD and MVD; however, four ebolaviruses (members of the genus *Ebolavirus*) cause disease, with EBOV only being one of them, and two marburgviruses (members of the genus *Marburgvirus*) cause disease, with Marburg virus (MARV) being one of them. The terms 'Ebola virus disease' and 'Marburg virus disease' are therefore ambiguous: either ICD-10 does not capture diseases caused by ebolaviruses and marburgviruses other than EBOV and MARV or EVD and MVD are cover terms for diseases caused by all ebolaviruses and marburgviruses (MARV and Ravn virus (RAVV)), requiring authors to specify which ebolavirus or marburgvirus caused a particular EVD or MVD outbreak. These ambiguities cause major confusion in communication among researchers and copy editors who are not necessarily familiar with the differences between 'Ebola virus' and 'ebolavirus' or

¹Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.

*e-mail: kuhnjens@mail.nih.gov

For a full list of author affiliations see the online version.

<https://doi.org/10.1038/s41579-019-0187-4>

Box 1 | New WHO-accepted filovirus disease classification

Main disease category: 1D60 Filovirus disease (FVD)

- First disease subcategory: 1D60.0 Ebola disease (EBOD)
 - Second disease subcategories: 1D60.00 Bundibugyo virus disease (BVD)^a; 1D60.01 Ebola virus disease (EVD)^b; 1D60.02 Sudan virus disease (SVD)^c; 1D60.03 Atypical Ebola disease; 1D60.0Y Other specified Ebola disease^d; 1D60.0Z Ebola disease, virus unspecified
- First disease subcategory: 1D60.1 Marburg disease (MARD)
 - Second disease subcategories: 1D60.10 Marburg virus disease (MVD)^e; 1D60.11 Atypical Marburg disease; 1D60.1Y Other specified Marburg disease; 1D60.1Z Marburg disease, virus unspecified
- First disease subcategory: 1D60.Y Other specified filovirus disease
- First disease subcategory: 1D60.Z Filovirus disease, virus unspecified

ICD-11, The International Classification of Diseases Revision 11. ^aCaused by Bundibugyo virus (BDBV). ^bCaused by Ebola virus (EBOV). ^cCaused by Sudan virus (SUDV). ^dCaused by, for instance, Taï Forest virus (TAFV). ^eCaused by Marburg virus (MARV) or Ravn virus (RAVV).

‘Ebola virus disease due to Ebola virus infection’ versus ‘Ebola virus disease due to Bundibugyo virus infection’¹. Consequently, the expert panel debated whether the EVD and MVD entries in ICD-10 should be merged into a single entry, whether the two terms should be split into several entries based on aetiological agents or whether a hierarchical scheme should be adopted to cover both possibilities.

Official virus taxonomy may change annually through decisions made by the International Committee on Taxonomy of Viruses (ICTV), but ICD updates and revisions are released at much longer intervals. Hence, the ICD cannot keep pace with taxonomic developments. Independence of ICD-11 filovirus disease names from virus taxonomy considerations was therefore thought to be imperative.

Results of expert panel discussions

A single umbrella term for the diseases caused by filoviruses is urgently needed, as differentiation between ICD-10’s EVD and MVD on clinical grounds alone is impossible. Following the publication of the ‘WHO Best Practices for the Naming of New Human Infectious Diseases’, this parent disease name should not contain any geographical locations; people’s names; species or class of animal or food; cultural, population, industry or occupational references; or components that incite undue fear^{2,3}. Furthermore, the panel almost unanimously discouraged the use of ‘haemorrhagic fever’ for any filovirus-associated disease name because ‘haemorrhagic fever’ is not unambiguously defined, and the majority of filovirus-infected individuals do not develop overt haemorrhage. Consequently, health-care workers could misdiagnose filovirus diseases, or potentially infected individuals may not seek admittance to a treatment unit based on the absence of haemorrhage. After thorough consideration, ‘Filovirus disease (FVD)’ was chosen as the ICD-11 parent disease term. Because filoviruses comprise a distinct and monophyletic group of viruses, the expert panel felt that the prefix ‘filo-’ was unlikely to disappear in the near future if taxonomic changes to the virus family would be required. Additional subcategories should be established to codify diseases caused by filovirus that

have not yet been associated with filovirus disease or yet-to-be-discovered novel filoviruses, diseases very likely caused by filoviruses without final agent confirmation, and filovirus diseases with ‘unusual’ clinical presentations.

The panel advocated for two subcategories to the filovirus parent entry for ebolavirus and marburgvirus diseases and recommended, if necessary, further subcategorization. The classical distinction of ICD-10’s EVD and MVD was felt to be important for traditional and familiarity reasons. Furthermore, molecular evidence is accumulating that ebolaviruses and marburgviruses behave differently *in vitro* and *in vivo*, suggesting that differences in clinical presentation of infections with ebolaviruses or marburgviruses will become evident in the future. ‘Ebola disease (EBOD)’ and ‘Marburg disease (MARD)’ were chosen for the major FVD subcategories (BOX 1): FVD due to ebolavirus and marburgvirus infections, respectively. The WHO naming guidelines were not applied in coining these terms because both ‘Ebola’ and ‘Marburg’ have been components of filovirus disease names since the 1970s and 1960s, respectively. The absence of the word ‘virus’ in the two disease names makes them taxonomically independent and therefore stable.

The panel then reintroduced the ICD-10 names ‘Ebola virus disease (EVD)’ and ‘Marburg virus disease (MVD)’ as EBOD and MARD subcategories because of their familiarity to the filovirus research community but restricted the use of EVD and MVD to diseases caused by agents belonging to only one species: EBOV (species *Zaire ebolavirus*), and MARV and RAVV (both species *Marburg marburgvirus*), respectively. Two additional EBOD subcategory disease terms were added to cover the remaining pathogenic filoviruses that have caused more than one registered human infection: Bundibugyo virus disease (BVD) and Sudan virus disease (SVD). Three additional subcategories for both EBOD and MARD were proposed: ‘Atypical Ebola/Marburg disease’ for EBOD or MARD patients with unusual clinical presentations; ‘Other specified Ebola/Marburg disease’ for EBOD or MARD patients infected with ebolaviruses or marburgviruses not covered by BDV, EVD and SVD or MVD (for example, disease due to Taï Forest virus infection); and ‘Ebola/Marburg disease, virus unspecified’ for patients who are suspected to be infected with an ebolavirus or marburgvirus in absence of virus identification.

The expert panel did not establish a separate category for filovirus-induced sequelae in filovirus disease survivors (for example, ‘post-Ebola syndrome’) as ICD-11 allows combinatorial coding (for example, ‘Atypical Ebola disease’ plus ‘Arthritis’).

New official filovirus disease names

The panel submitted a proposal containing the proposed filovirus disease classification and nomenclature to the WHO’s ICD-11 Proposal Platform in April 2018. After peer review and appropriate revisions, the new filovirus disease classification and nomenclature (BOX 1; Supplementary Table 4) were accepted in May 2018 and subsequently incorporated into the

ICD-11 framework. The panel recommends that the new filovirus disease names and abbreviations be used immediately in forthcoming filovirus publications to ensure a seamless transition once ICD-11 is adopted by United Nations member states.

1. Kuhn, J. H. in *Marburg- and Ebolaviruses — From Ecosystems to Molecules* (eds Mühlberger, E., Hensley, L. L. & Townner, J. S.) 447–460 (Springer, 2017).
2. Fukuda, K., Wang, R. & Vallat, B. Naming diseases: first do no harm. *Science* **348**, 643 (2015).
3. Kupferschmidt, K. Rules of the name. *Science* **348**, 745 (2015).

Acknowledgements

The authors thank Laura Bollinger (US National Institutes of Health (NIH)/US National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility at Fort Detrick, Frederick, MD, USA) for critically reviewing the manuscript. This work was supported in part through Battelle Memorial Institute's prime contract with the NIAID under Contract No. HHSN272200700016I (J.H.K.). This project was funded in part with federal funds from the National Cancer Institute, NIH, under Contract No. HHSN261200800001E (I.C.). G.I. is grateful for support from the Italian Ministry of Health, grant Ricerca Corrente, Research Programme n.1. The UK Public Health Rapid Support Team (D.G.B.) is funded by the UK Department of Health and Social Care.

Competing interests

The authors declare no competing interests.

Disclaimer

The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official views, assertions, opinions or policies, either expressed or implied, of the US Department of Defense, US Department of Health and Human Services (National Institutes of Health; Centers for Disease Control and Prevention), US Uniformed Services University, UK National Health System, the UK National Institute for Health Research, the UK Department of Health and Social Care or of the institutions and companies affiliated with the authors. In no event shall any of these entities have any responsibility or liability for any use, misuse, inability to use, or reliance upon the information contained herein. Some authors are employees of the U.S. Government and as such under the provisions of 17 U.S.C. 105, copyright protection is not available for this work. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.

Supplementary information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41579-019-0187-4>.

RELATED LINKS

ICD-10: <https://icd.who.int/browse10/2016/en>

ICD-11: <https://icd.who.int/browse11/l-m/en>